Business Wire

Tsing Hua University Hospital Preparatory Office Officially Opens in Taoyuan

22.9.2022 12:00:00 EEST | Business Wire | Press release

Share

On August 20, the Tsing Hua University Hospital Preparatory Office was officially opened in the Xinkong Building at the Taoyuan Metro Corporation’s Qingpu Depot, which is only one MRT station away from the site where the Hospital will be built.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

At the opening ceremony (right to left): NTHU senior vice presidents Tai Nyan-hwa and Lyu Ping-chiang, NTHU president W. John Kao, Taoyuan City mayor Cheng Wen-tsan, former NTHU president Hocheng Hong, Taoyuan Metro chairman Liu Kun-I, and Taoyuan Aerotropolis chairman Chen Si-jhen. (Photo: National Tsing Hua University)

NTHU and the Taoyuan City Government have already signed a letter of intent outlining their plan to jointly establish a world-class medical center that will serve the local community; the plan also includes assistance in the training of bilingual teachers and support for science education and experimental education at Taoyuan’s kindergartens, primary, and secondary schools.

The Preparatory Office was officially inaugurated by Taoyuan City mayor Cheng Wen-tsan and NTHU president W. John Kao.

Mayor Cheng has played a key role in the early stages of the Hospital project. He pointed out that Taiwan is good at both electronics and medical care, both of which are taught at NTHU, and that’s why he has been such a staunch supporter of NTHU through all the difficulties which have arisen in the planning stage.

Cheng emphasized that it will take only ten minutes for an ambulance to go from the Taoyuan International Airport to the emergency room at the new hospital; and that in addition to cosmetic surgery and health examinations, the Hospital will also provide critical care and boron neutron capture therapy (BNCT).

Moreover, the Hospital is expected to become a leading center for the development of advanced cell regeneration technology.

President Kao said that this is a very important day for NTHU, in that the school has long had its sights set on medical education, and now the dream has finally come true, noting that “Today is a new milestone in this 50-kilometer journey from NTHU to Taoyuan, which has been going on for some 66 years.”

Kao also noted that this year could be seen as the “year of medicine” at NTHU, since the first batch of medical students has recently been enrolled.

The Hospital will be located near the Hengshan Station (A16) of the Airport MRT line, on a parcel of land provided by Taoyuan City. The size of the parcel is 7.2 hectares, of which 5 hectares will be used for the Hospital itself, while the remaining 2.2 hectares will be used for the affiliated teaching and research facilities.

NTHU senior vice president Lyu Ping-chiang said that the BOT agreement will be finalized by the end of this year, and that construction will start next year, soon after the parcel is transferred. The Hospital is expected to be completed by the end of 2027 and opened in 2028.

The Hospital will initially have 200 general acute care beds, plus an intensive care unit, a respiratory care unit, negative pressure isolation rooms, and a psychiatric unit for both inpatients and outpatients, all of which will be gradually expanded over a number of years to reach a total capacity of 910 beds.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 10:00:00 EET | Press release

Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release

VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye